NCT02362048View on ClinicalTrials.gov

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

ACP-196

DRUG

ACP-196 in combination with pembrolizumab

Trial Locations (1)

Unknown

Houston

Sponsors

Lead Sponsor

Acerta Pharma BV

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY